BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 6441302)

  • 1. Masking of fibrinolytic response to stimulation by an inhibitor of tissue-type plasminogen activator in plasma.
    Brommer EJ; Verheijen JH; Chang GT; Rijken DC
    Thromb Haemost; 1984 Oct; 52(2):154-6. PubMed ID: 6441302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different tissue plasminogen activator release in the arm and leg during venous occlusion is equalized after DDAVP infusion.
    Keber D; Stegnar M; Kluft C
    Thromb Haemost; 1990 Feb; 63(1):72-5. PubMed ID: 2111049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal and hepatic handling of endogenous tissue-type plasminogen activator (t-PA) and its inhibitor in man.
    Brommer EJ; Derkx FH; Schalekamp MA; Dooijewaard G; vd Klaauw MM
    Thromb Haemost; 1988 Jun; 59(3):404-11. PubMed ID: 3142078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of desmopressin acetate (DDAVP) as a test of the fibrinolytic capacity of patients--analysis of responders and non-responders.
    Brommer EJ; Barrett-Bergshoeff MM; Allen RA; Schicht I; Bertina RM; Schalekamp MA
    Thromb Haemost; 1982 Oct; 48(2):156-61. PubMed ID: 6817444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Thromboembolic disease and anomalies of fibrinolysis].
    Juhan-Vague I; Aillaud MF; Valadier J; Alessi MC; Serradimigni A
    Ann Med Interne (Paris); 1986; 137(6):471-4. PubMed ID: 3101564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dynamic test to investigate potential tissue plasminogen activator activity. Comparison of deamino-8-D-argininevasopressin with venous occlusion in normal subjects and patients.
    Sultan Y; Harris A; Strauch G; Venot A; De Lauture D
    J Lab Clin Med; 1988 Jun; 111(6):645-53. PubMed ID: 3131470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric patients.
    Brommer EJ; Schicht I; Wijngaards G; Verheijen JH; Rijken DC
    Thromb Haemost; 1984 Dec; 52(3):311-4. PubMed ID: 6085194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis.
    Francis RB; McGehee WG; Feinstein DI
    Thromb Haemost; 1988 Jun; 59(3):412-4. PubMed ID: 3142079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood fibrinolysis and the response to desmopressin in glomerulonephritis.
    Brommer EJ; Van den Wall Bake AW; Dooijewaard G; van Loon BJ; Emeis JJ; Weening JJ
    Thromb Haemost; 1994 Jan; 71(1):19-25. PubMed ID: 8165642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impaired fibrinolytic response to DDAVP in patients with von Willebrand's disease.
    Sultan Y; Loyer F; Venot A
    Nouv Rev Fr Hematol (1978); 1992; 34(1):55-60. PubMed ID: 1523100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrinolytic and haemostatic responses to desamino-D-arginine vasopressin (DDAVP) administered by intravenous and subcutaneous routes in healthy subjects.
    MacGregor IR; Roberts EM; Prowse CV; Broomhead AF; Ozolins M; Litka P
    Thromb Haemost; 1988 Feb; 59(1):34-9. PubMed ID: 3129807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DDAVP induces systemic release of urokinase-type plasminogen activator.
    Levi M; ten Cate JW; Dooijewaard G; Sturk A; Brommer EJ; Agnelli G
    Thromb Haemost; 1989 Sep; 62(2):686-9. PubMed ID: 2510348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.
    Juhan-Vague I; Valadier J; Alessi MC; Aillaud MF; Ansaldi J; Philip-Joet C; Holvoet P; Serradimigni A; Collen D
    Thromb Haemost; 1987 Feb; 57(1):67-72. PubMed ID: 3109059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daytime fluctuations in blood of tissue-type plasminogen activator (t-PA) and its fast-acting inhibitor (PAI-1).
    Kluft C; Jie AF; Rijken DC; Verheijen JH
    Thromb Haemost; 1988 Apr; 59(2):329-32. PubMed ID: 3133814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory response of the vessel wall to DDAVP and venous occlusion in von Willebrand's disease.
    Bykowska K; Letowska M; Sabliński J; Binder BR; Kopeć M; Lopaciuk S
    Acta Haematol Pol; 1994; 25(3):261-8. PubMed ID: 7992599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma fibrinolytic activity in patients undergoing major abdominal surgery.
    Mellbring G; Dahlgren S; Wiman B
    Acta Chir Scand; 1985; 151(2):109-14. PubMed ID: 3873768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Poor fibrinolytic response to venous occlusion: defect of endothelial cells or plasma interference?].
    Stalder M; Hauert J; Bachmann F
    Schweiz Med Wochenschr; 1983 Oct; 113(40):1462-4. PubMed ID: 6606226
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 1-Desamino-8-D-arginine vasopressin (DDAVP) in patients with congenital nephrogenic diabetes insipidus.
    Brink HS; Derkx FH; Boomsma F; Brommer EJ; Schalekamp MA
    Neth J Med; 1993 Aug; 43(1-2):5-12. PubMed ID: 8232694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reproducibility of fibrinolytic response to venous occlusion in healthy subjects.
    Stegnar M; Mavri A
    Thromb Haemost; 1995 Mar; 73(3):453-7. PubMed ID: 7667828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep vein thrombosis and fibrinolysis. Defective urokinase type plasminogen activator release.
    Levi M; Lensing AW; Büller HR; Prandoni P; Dooijewaard G; Cuppini S; ten Cate JW
    Thromb Haemost; 1991 Oct; 66(4):426-9. PubMed ID: 1796391
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.